LaFleur & Godfrey LLC Has $2.72 Million Stake in Zoetis Inc. $ZTS

Key Points

• LaFleur & Godfrey LLC has reduced its holdings in Zoetis Inc. by 34.7%, ending the most recent quarter with 17,414 shares valued at approximately $2.72 million.
• Zoetis reported quarterly earnings of $1.76 per share, exceeding estimates by $0.14, along with revenues of $2.46 billion for the quarter.
• Investment analysts have a consensus target price of $200.88 for Zoetis, with several firms providing varying ratings, including the upgrade to "overweight" by Piper Sandler.

LaFleur & Godfrey LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 34.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,414 shares of the company's stock after selling 9,240 shares during the period. LaFleur & Godfrey LLC's holdings in Zoetis were worth $2,716,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in ZTS. Portside Wealth Group LLC boosted its stake in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after buying an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its holdings in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after acquiring an additional 1,760 shares during the period. Horizon Financial Services LLC acquired a new stake in shares of Zoetis during the 1st quarter worth $380,000. Finally, Sage Rhino Capital LLC increased its position in shares of Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $145.82 on Monday. The stock has a market capitalization of $64.63 billion, a PE ratio of 25.10, a PEG ratio of 2.34 and a beta of 0.89. The business's 50 day simple moving average is $151.25 and its 200 day simple moving average is $156.45. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $139.70 and a one year high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZTS. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Argus reaffirmed a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.